Company: CRNX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0000950170-25-029050
Chunk: 51

Company: Crinetics Pharmaceuticals, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 14
Chunk 51
---
 of net loss to net cash used in operating activities:

    Stock-based compensation

    69,386

    40,937

    28,268

    Depreciation and amortization

    2,785

    1,098

    983

    Noncash lease expense

    3,042

    1,210

    406

    Accretion of purchase discounts and amortization     of premiums on investment securities, net

    (14,931
    )

    (6,271
    )

    34

    Noncash license revenues

    —

    (2,000
    )

    —

    Loss on equity method investment

    470

    5,198

    1,010

    Loss on disposal of property and equipment

    51

    6

    —

    Change in valuation of derivative asset

    —

    —

    (600
    )

    Increase (decrease) in cash resulting from changes in:

    Prepaid expenses and other assets

    (5,974
    )

    (4,523
    )

    215

    Accounts payable and accrued expenses, compensation and related expenses, and other non-current liabilities

    17,541

    14,648

    10,994

    Deferred revenue

    74

    (1,535
    )

    8,341

    Operating lease liabilities

    (6
    )

    (546
    )

    (938
    )

    Net cash used in operating activities

    (225,970
    )

    (166,307
    )

    (115,205
    )

    Investing activities:

    Purchases of investment securities

    (1,146,772
    )

    (527,857
    )

    (329,817
    )

    Purchase of Radionetics preferred stock

    —

    (5,000
    )

    —

    Maturities of investment securities

    575,799

    337,132

    157,493

    Purchases of property and equipment

    (3,844
    )

    (4,688
    )

    (1,656
    )

    Net cash used in investing activities

    (574,817
    )

    (200,413
    )

    (173,980
    )

    Financing activities:

    Proceeds from issuance of common